Top ▲
The non-mevalonate (MEP) pathway of isoprenoid precursor biosynthesis is utilized by bacteria, plants and apicomplexan protozoa but is not present in mammals (complete pathway for P. falciparum is available at www.wikipathways.org). Enzymes of this pathway represent promising therapeutic targets for antimalarial drug development because the pathway is present in the Plasmodium parasite but not in the human host [1].
PfDXR (Plasmodium falciparum 1-deoxy-D-xylulose 5-phosphate reductoisomerase) C
Show summary »
More detailed page |
PfIspD (Plasmodium falciparum 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase) C
Show summary »
More detailed page |
Database page citation:
Non-mevalonate pathway enzymes. Accessed on 16/04/2021. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1055.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators. (2019) The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 176 Issue S1: S1-S20.